Premium
Targeting the gastrointestinal tract to develop novel therapies for HIV
Author(s) -
Reeves RK,
Burgener A,
Klatt NR
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.186
Subject(s) - human immunodeficiency virus (hiv) , gastrointestinal tract , antiretroviral therapy , medicine , pathogenesis , immunology , intensive care medicine , viral load
Despite the use of antiretroviral therapy (ART), which delays and/or prevents AIDS pathogenesis, human immunodeficiency virus (HIV)‐infected individuals continue to face increased morbidities and mortality rates compared with uninfected individuals. Gastrointestinal (GI) mucosal dysfunction is a key feature of HIV infection, and is associated with mortality. In this study, we review current knowledge about mucosal dysfunction in HIV infection, and describe potential avenues for therapeutic targets to enhance mucosal function and decrease morbidities and mortalities in HIV‐infected individuals.